Biogen (BIIB)
(Delayed Data from NSDQ)
$235.32 USD
+8.44 (3.72%)
Updated May 15, 2024 04:00 PM ET
After-Market: $234.90 -0.42 (-0.18%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 661 - 680 ( 799 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Buying Back Shares Is Good, Buying New Assets Is Better
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Anti-LINGO Miss May Be a Catalyst for Growth-Oriented BD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2016 Digestive Disease Week Recap
Provider: Rodman & Renshaw, Co.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2016 Digestive Disease Week Recap
Provider: H.C. Wainwright & Co., Inc.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector
Provider: H.C. Wainwright & Co., Inc.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector
Provider: Rodman & Renshaw, Co.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Emerging Themes from AAN: Cognitive Resilience in Alzheimers and Multiple Sclerosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Long-term Alzheimers Strategy Remains Strong; Reit Buy Rating and $360 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Industry Report ; PHARMA & BIOTECH; This report contains brief updates on the following: VRX, PFE, NVO, MNTA, CORT, BIIB, AMGN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: ZACKS INVESTMENT RESEARCH
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Using BAN2401s Trial Simulations to Inform Probability for Early Success and Dose Scenarios
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
A Closer Look at Eisai/BIIBs BAN2401 Bayesian Adaptive Phase 2 Design
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A